In the landscape of modern psychiatry, the treatment of first-episode psychosis (FEP) has long been anchored by the immediate administration of antipsychotic medications (APMs). However, a growing body of research and a rising chorus of patient voices are beginning to challenge this pharmacological status quo. A significant new study, led by Alona Schneidman of the University of Haifa and published in the Journal of Humanistic Psychology, offers a poignant look into the lived experiences of young adults navigating the complex journey of taking—and eventually seeking to discontinue—antipsychotic drugs.
The findings, which come from a qualitative analysis of participants who completed the NAVIGATE program in Israel, reveal a stark disconnect between clinical intentions and patient realities. The study underscores a pervasive sense of "emotional emptiness" and an "altered self" among users, while identifying the critical roles that clinical support and family dynamics play in the success or failure of medication tapering.
Main Facts: The Human Cost of the Pharmacological Shield
The study focused on 23 young adults who had recently completed NAVIGATE, a comprehensive first-episode psychosis recovery program. Despite the program’s intent to provide "personalized medication management," the subjective experience of the participants was overwhelmingly negative.
According to the data, 87% of the participants (20 out of 23) reported negative experiences with their medication prior to and during the program. While three participants noted benefits such as symptom reduction and better sleep, the majority described a profound sense of loss. The most common complaints were not merely physical side effects, but existential ones: emotional numbness, a "hollow" feeling, and a sense that the medication had fundamentally changed their personality.
The study’s findings on discontinuation patterns were equally telling. By the time of the interviews:
- 44% (10 participants) had completely stopped using antipsychotics.
- 26% (6 participants) had successfully reduced their dosage to a minimal level.
- 30% (7 participants) remained on their full dose, often citing family pressure rather than clinical necessity as the primary reason.
These statistics highlight a significant drive among young adults to move away from long-term antipsychotic use, a trend that aligns with emerging global research suggesting that for many, the long-term risks of these drugs may outweigh their initial benefits.
Chronology: From First Episode to the Search for Autonomy
The journey for these participants typically began with a crisis—the first episode of psychosis—followed by the standard clinical response: hospitalization and the initiation of high-dose antipsychotics. For many, this period was marked by a loss of agency.
The NAVIGATE Intervention
The participants eventually enrolled in NAVIGATE, a multi-disciplinary program designed to foster resilience. NAVIGATE includes family education, support for returning to work or school, and "resilience training." Crucially, it also includes a medication management component that, in theory, is more personalized than standard care.
The Desire for Reduction
The study notes that during the program, all 23 participants expressed a desire to either reduce or entirely discontinue their medication. This desire was not impulsive; it was a response to the cumulative burden of side effects and the feeling of being "stalled" in their personal recovery.
Post-Program Reflection
The interviews conducted by Schneidman’s team occurred after the participants had completed at least three months of the NAVIGATE program. This timing allowed participants to reflect on the transition from the "acute" phase of treatment to the "recovery" phase, where the long-term viability of staying on APMs became a central point of contention in their lives.
Supporting Data: The Phenomenological and Physical Burden
The University of Haifa study provides rich, qualitative data that sheds light on why the drive to discontinue is so high. The researchers identified three recurring themes: the experience of the "altered self," the physical toll of side effects, and the social stigma of being a "psychiatric patient."
1. The "Hollow Donut" and Emotional Erasure
Participants described the effects of APMs as a form of "internal darkness." One participant’s testimony stood out, comparing their experience to being "a hollow donut without the taste of life." This emotional blunting—the inability to feel joy, anger, or sadness—led many to feel "inhuman."
The study highlights that for young adults, whose developmental task is to form a stable identity, the "altered self" caused by medication is particularly damaging. "Every time I took a pill, I felt I was no longer myself," one interviewee remarked. This sense of being "another person" often hindered the very social reintegration that programs like NAVIGATE aim to achieve.
2. The Metabolic and Physical Toll
Nearly half of the participants (48%) cited significant physical challenges, most notably rapid weight gain. For young adults, the psychological impact of gaining 20 to 25 kilograms (44 to 55 lbs) is profound. One participant noted that the weight gain made them feel "ugly" and "upset," adding a layer of depression and body dysmorphia to their existing mental health challenges.
3. The Stigma of the "Madhouse"
The medication served as a constant, visible reminder of their diagnosis. Six participants spoke specifically about the "label of being crazy." For these individuals, discontinuing medication was not just about biology; it was a symbolic act of shedding the identity of a "mental patient" and reclaiming their status as a "normal" member of society.
Official Responses and Clinical Context: The Tapering Debate
The findings by Schneidman and her colleagues do not exist in a vacuum. They are part of a broader, often contentious debate within the psychiatric community regarding the ethics and safety of antipsychotic tapering.
The Reluctance of the Medical Establishment
While the Haifa study found that 19 of the 23 participants felt supported by their clinicians in shared decision-making, other research suggests this is not the norm. A 2023 study highlighted that many mental health staff members remain deeply reluctant to assist in tapering, fearing relapse or legal liability. Some service users have gone as far as to label psychiatric professionals as the "least helpful factor" in their attempts to quit.
Ethical Responsibility vs. Clinical Fear
Despite this reluctance, a growing number of experts argue that it is a clinician’s ethical responsibility to support a patient’s request to reduce medication, provided it is done safely. The University of Haifa study supports this, showing that when clinicians provide a "safe, non-judgmental environment," patients are more likely to navigate the discontinuation process successfully without a catastrophic relapse.
The Family Barrier
One of the most significant "official" or external barriers identified was family reluctance. Parents, often traumatized by the initial psychotic episode, frequently viewed the medication as a "safety net." In several cases, participants reported that even when their psychiatrist agreed to a lower dose, their parents forbade it. "They are terrified of another attack," one participant explained. This highlights the need for family-based interventions that address the parents’ fears as much as the patient’s symptoms.
Implications: A New Paradigm for Psychosis Treatment
The implications of this study are far-reaching, suggesting that the current "medication-first and medication-forever" model may be failing a significant portion of the FEP population.
Better Long-Term Outcomes Through Discontinuation
The study’s findings align with previous research showing that starting antipsychotics too early (within the first month of FEP) can actually lead to worse long-term outcomes and impaired cognitive functioning. Conversely, data suggests that patients who are able to successfully stop taking antipsychotics within two years of their first episode have a recovery rate six times higher than those who remain on the drugs long-term.
The Necessity of Slow Tapering
The study reinforces the importance of "hyperbolic" or very slow tapering. Many of the "relapses" feared by families and doctors are, in fact, severe withdrawal symptoms—often described by patients as "the stuff of demonic nightmares." By acknowledging these as withdrawal rather than a return of the underlying illness, clinicians can better manage the transition.
The Shift to First-Person Psychopharmacology
This research contributes to the emerging field of "first-person psychopharmacology," which prioritizes the patient’s subjective experience of a drug over the clinician’s objective observation of symptom reduction. If a drug "fixes" a hallucination but "breaks" the person’s ability to feel human, the Haifa study suggests the treatment cannot be considered a success.
Conclusion
The work of Alona Schneidman and her team serves as a call to action for more nuanced, person-centered care in the treatment of psychosis. By identifying the facilitators of success—mutual decision-making and education on withdrawal—and the barriers of family fear and clinical reluctance, the study provides a roadmap for a more humane psychiatric practice. For young adults at the start of their lives, the goal of treatment should not merely be the absence of psychosis, but the presence of a self worth living as.
Reference:
Schneidman, A., Roe, D., Zisman-Ilani, Y., & Shpigelman, C.-N. (2025). Perceptions and experiences of antipsychotic use and discontinuation among young adults who completed a first-episode psychosis program. Journal of Humanistic Psychology.
